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A B S T R A C T
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety
monitoring and management) to better describe the safety proﬁle of new treatment regimens for drug-
resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difﬁcult to
implement in several countries.
The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers
and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new
anti-TB drugs.
Following a pilot study carried out in 2016, ofﬁcial involvement of TB reference centres/countries into
the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were
consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a
speciﬁc drug based on its known safety proﬁle.
A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with
bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating
countries had committed to report by the ﬁrst quarter of 2019.
© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The World Health Organization (WHO) seeks global evidence
on the safety and tolerability of new treatment regimens for drug-
resistant tuberculosis, including multidrug-resistant tuberculosis
(MDR-TB) (Halleux et al., 2018).
The WHO launched a comprehensive approach, known as
aDSM (active TB drug safety monitoring and management)
(World Health Organization, 2015), proposing that national
programmes implement ‘active and systematic clinical and
laboratory assessment of patients on treatment with new TB
medicines, or novel MDR-TB or XDR (extensively drug-resis-
tant)-TB regimens to detect, manage and report suspected or
conﬁrmed drug toxicities’ (Halleux et al., 2018). This initiative is
really important as, after more than 40 years without any new
drug speciﬁcally licensed to manage TB, we ﬁnally have
bedaquiline and delamanid (Borisov et al., 2017; Kim et al.,
2018; Kuksa et al., 2017; Mohr et al. 2018; Pontali et al., 2017;
Pontali et al., 2018; Pym et al., 2016).
Although some information on safety of the new drugs has been
made available, more clinical details (to obtain through extensive
surveillance of adverse events (AEs)) are required. This is
particularly relevant in view of the potential bedaquiline,
delamanid, clofazimine, and quinolones have to increase the QT
interval (Pontali et al., 2017) and generate an arrhythmic event.
Therefore, the real-time monitoring of anti-TB regimens is fully
justiﬁed (Halleux et al., 2018; World Health Organization, 2015). Of
course, although any kind of AE requires prompt clinical action,
special attention is necessary on serious AEs, as they are potentially
life-threatening. In particular, according to the WHO aDSM project
serious AEs include death or a life-threatening experience,
hospitalization or prolongation of hospitalization, persistent or
signiﬁcant disability, or congenital anomaly (Halleux et al., 2018;
World Health Organization, 2015).
The WHO proposal to national programmes was to initiate
regular monitoring of AEs, as well as collect and report information
Figure 1. Map of the participating countries.
Red: Countries which regularly reported; Green: Countries in the process of reporting; Blue: Countries which activated active monitoring of adverse events with no cases yet
treated with new drugs.
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on bacteriological status at diagnosis (sputum smear, culture, drug
resistance proﬁle), bacteriological conversion/reversion (sputum
smear and culture conversion rates) and treatment outcomes
(Halleux et al., 2018). The surveillance methodology has been left
to countries which were supposed to use electronic registers or
existing electronic medical record systems (Halleux et al., 2018),
complementing, rather than duplicating, national pharmacovigi-
lance initiatives.
WHO also launched a global aDSM database to collect a
standard set of variables including anonymised individual-level
patient data on serious AEs (Halleux et al., 2018), and provided
clear guidance on how to implement aDSM at a national level
(World Health Organization, 2015).
National TB Programmes faced difﬁculties in implementing
aDSM and contributing to the global database. Taking advantage of
a newly implemented global network (Global Tuberculosis
Network-GTN) (Borisov et al., 2017; Rossato Silva et al., 2018) a
large aDSM project was launched to demonstrate the feasibility of
implementing national aDSM registers. The GTN research
addressed clinical centres with the goal of assessing the safety
and tolerability proﬁle, as well as the effectiveness of anti-TB drugs
and regimens in MDR-TB patients treated with new drugs
(bedaquiline, delamanid) worldwide. The WHO initiative is
focused on National Tuberculosis Programmes in order to evaluate
the safety of anti-TB regimens. The two initiatives are co-ordinated.
After a pilot study was implemented in 2016 in a few centres to
assess the suitability of the project and its potential implementa-
tion, and following the approval of the coordinating centre’s Ethics
Committee (July 11th, 2017), the project was proposed to the
clinical centres or national programmes participating in the
network. Each centre or country signed a conﬁdentiality and
data-sharing agreement with the coordinating centre and obtained
local Ethics Committee clearance as per legislation in force.
All consecutive cases for which bedaquiline and/or delamanid
were prescribed since the moment the centre or country adhered
to the project were enrolled. The AEs of any drug involved in the
treatment regimen were prospectively collected, ensuring a
probabilistic mechanism of causality assignment (e.g. attribution
of the AE to a speciﬁc drug based on its evidence-based proﬁle).
The data collection form in an electronic format was based on the
WHO-recommended template, although more clinical details were
requested (World Health Organization, 2015).
Table 1
Participating countries and details on the cases reported.
Countries Estimated
casesa
N
Estimated
coverageb
%
Cases enrolled
N
Male
N (%)
Cases
treated
with Bdq
N (%)
Cases
treated
with Dlm
N (%)
Cases treated with Bdq-Dlm
or Dlm-Bdq consecutively N
(%)
Cases treated with
Bdq-Dlm in
combination N (%)
EUROPE
Belgium 3 60 3 2 (67) 3 (100) 0 (0) 0 (0) 0 (0)
Belarusf 113 80 27 17 (63) 20 (74) 7 (26) 0 (0) 0 (0)
Italyg 29 80 27 17 (63) 20 (74) 6 (25) 0 (0) 1 (4)
Latvia 30 100 30 18 (60) 20 (40) 3 (10) 1 (3) 6 (20)
Lithuania 170 100 Data uploading – – – – –
Macedonia No cases 100 – – – – – –
Netherlandsf 6 100 6 5 (83) 3 (50) 0 (0) 1 (17) 2 (33)
Portugal 1 100 1 1 (100) 0 (0) 1 (100) 0 (0) 0 (0)
Russian Federationf 257 100c 140 87 (62) 135 (96) 2 (1) 1 (0.7) 2 (1)
Serbia No cases 100 – – – – – –
Slovakia 1 100 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Spaing 9 100 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Sweden 16 100 5 2 (40) 4 (80) 0 (0) 1 (20)i 0 (0)
United Kingdom 4 20 4 2 (50) 4 (100) 0 (0) 0 (0) 0 (0)
AFRICA
Niger 21 100 13 13
(100)
10 (77) 0 (0) 0 (0) 3 (23)
Sudan 5 100 2 2 (100) 2 (100) 0 (0) 0 (0) 0 (0)
LATIN AMERICA
Argentina 11 100 3 0 (0) 3 (100) 0 (0) 0 (0) 0 (0)
Brazil 33 100 26 22 (85) 26 (100) 0 (0) 0 (0) 0 (0)
Colombia No cases 100 – – – – – –
Mexicof 8 100 4 3 (75) 1 (25) 1 (25) 0 (0) 2 (50)
Paraguay No cases 100 – – – – – –
Peru 30 80 Data uploading – – – – –
ASIA
Chinah 5 100d Data uploading – – – – –
India 15 100e 10 5 (50) 9 (90) 0 (0) 1 (10) 0 (0)
Malaysiah 8 100 Data uploading – – – – –
United Arab
Emirates
No cases – – – – – – –
OCEANIA
Australia 6 100e 6 4 (67) 6 (100) 0 (0) 0 (0) 0 (0)
TOTAL 27 781 Range 20%–100% 309 200
(65)
268 (87) 20 (7) 5 (2) 16 (5)
a Cases estimated by countries to be fully reported by 1st quarter 2019.
b Countries’ estimate of the national coverage of the aDSM project on new drugs.
c In the 2 Oblasts reporting.
d In the Province reporting.
e In the State reporting.
f 2 centres.
g 6 centres.
h 1 centre.
i Case with Dlm for 4 days only, not concomitant with Bdq.
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This article reports on the initial results of the aDSM project.
As of January 31st 2019 (interim analysis), 41 centres in 27
countries(Figure1,Table1)providedaDSMinformationonnewanti-
TB drugs: 14 in Europe, 6 in Latin America, 4 in Asia, 2 in Africa, and 1
in Oceania. 5 countries participated in the aDSM project although no
case has yet been treated with bedaquiline and/or delamanid.
This resulted in 100% coverage for the majority of the countries,
while in some of them the actual coverage was lower. In the
Russian Federation 2 Regions (Moscow and Arkhangelsk Oblasts)
are represented with 100% coverage, as well as the Victoria State in
Australia and the Zhejiang Province in China.
A total of 309 cases were fully reported from January 2016 to
January 2019 (65% males; 268 treated with bedaquiline, 20 with
delamanid and 21 with the two drugs prescribed in combination or
consecutively) out of the estimated 781 cases the participating
countries committed to report in the ﬁrst quarter 2019.
The recruitment process in all continents was long and time-
consuming, although the support and enthusiasm of the partici-
pating colleagues allowed for resolution of any existing problems.
Several countries (including Sub-Saharan Africa) were asked to
participate, but some centres decided to decline as the project is on
a voluntary basis and the activity is perceived as ‘difﬁcult’ ‘or time-
consuming’ without provision for additional resources.
During the ‘interim analysis’, planned in the second quarter 2019,
AEswillbeanalysedseparatelybothperdrug(bedaquiline,delamanid,
linezolid, ﬂuoroquinolones, clofazimine, etc.) and per ‘severity’ status.
To our knowledge, this is the ﬁrst published evidence of a global
aDSM project in the literature.
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